xgene logo

May 08,2024

Xgene Pharmaceutical Pty Ltd. Announced the Enrollment of the First Cohort in the Phase I clinical trial of XG2002 capsules, a novel selective TRPM8 channel blocker.

xgene logo

April 08,2024

Xgene Pharmaceutical Pty Ltd. Announced that XG005 Phase II Clinical Trial of Keen Osteoarthritis in China Has Completed the Enrollment of Target Subjects

xgene logo

March 11,2024

Xgene Pharmaceutical Pty Ltd. Receives HREC’s approval to initiate a First-In-Human (FIH) trial of its innovative analgesic product XG2002

xgene logo

August 23,2023

Xgene Pharmaceutical Inc. Announces Dosing of First Patient in a Phase 2b/3 Trial of XG005 for the Treatment of Pain Following Bunionectomy Surgery.

xgene logo

April 26,2023

Xgene Pharmaceutical Announces Positive Top-Line Results from Phase 1b/2a Trial of Topical Gel XG004 for the Treatment of Osteoarthritis (OA) Pain of the Knee

xgene logo

November 04,2021

Xgene Pharmaceutical secures $40m in Series C


September 22,2021

Xgene Pharmaceuticals Co. Ltd.and RaQualia Pharma Inc.have entered into a licensing agreement for a novel TRPM8 blocker discovered by RaQualia Pharma


April 22,2020

NDA Application of XG005 will follow a 505(B)(1) regulatory pathway


May 4, 2019

XGene Pharmaceutical Closed the B Plus

Round Financing


October 25, 2018

XGene Pharmaceutical Closed US$20 Million B Round Financing